Merck Sells Contract Biopharmaceutical Business to Fujifilm - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Merck Sells Contract Biopharmaceutical Business to Fujifilm

ePT--the Electronic Newsletter of Pharmaceutical Technology

Fujifilm and Merck & Co. have formed a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a contract biopharmaceutical manufacturing and development business of Merck.

Under the agreement, Fujifilm will purchase all of the equity interests in two Merck subsidiaries, Diosynth RTP and MSD Biologics (UK), which together own all assets of the Merck BioManufacturing Network. The network consists of facilities of Diosynth in Research Triangle Park, North Carolina, and MSD Biologics (UK) in Billingham, United Kingdom, as well as the related manufacturing contracts, business-support operations, and workforce. The former Merck business provides CGMP contract-manufacturing services for recombinant proteins, vaccines, and monoclonal antibodies. As part of the agreement, Merck has committed to certain continued development and manufacturing activities with these two companies. Financial details of the transaction were not disclosed. The transaction is subject to customary closing conditions.

"Fujifilm continues to build upon its ongoing commitment to delivering pharmaceutical business," said Shigetaka Komori, president and CEO of Fujifilm, in a Feb. 28, 2011, Merck press release. "This acquisition provides an important addition to our pharmaceutical business with diverse capabilities and technical expertise in production of protein therapeutics."

Merck had built its contract biopharmaceutical business through acquisitions. In late 2009, Merck acquired the Billingham site from the contract-manufacturing organization Avecia. Diosynth was part of Akzo Nobel, and in 2007, Schering-Plough acquired the human and animal-health business of Akzo Nobel. Merck acquired Schering-Plough in 2009.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here